Taxation (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Taxation [Abstract] |
|
| Schedule of Income Tax Provision |
The income tax provision consisted of the following components:
| | |
For the years ended December 31, | |
| | |
2023 | | |
2024 | | |
2025 | |
| Current income tax expense | |
$ | 1,871 | | |
$ | 1,618 | | |
$ | 1,353 | |
| Deferred income tax expense/(benefit) | |
| 701 | | |
| 1,235 | | |
| (1,007 | ) |
| Total income tax expense | |
$ | 2,572 | | |
$ | 2,853 | | |
$ | 346 | |
|
| Schedule of Provision for Income Taxes and the Provision at the PRC, Mainland Statutory Rate |
A reconciliation between the Group’s actual
provision for income taxes and the provision at the PRC, mainland statutory rate is as follows:
| | |
For the years ended December 31, | |
| | |
2023 | | |
2024 | | |
2025 | |
| (Loss)/income before income tax expense | |
$ | (15,007 | ) | |
$ | (61,600 | ) | |
$ | (2,053 | ) |
| Computed income tax (benefit)/expense with statutory tax rate | |
| (3,752 | ) | |
| (15,400 | ) | |
| (513 | ) |
| Additional deduction for research and development expenses | |
| (546 | ) | |
| (439 | ) | |
| (552 | ) |
| Tax effect of preferred tax rate | |
| 2,264 | | |
| 15,696 | | |
| 791 | |
| Tax effect of favorable tax rates on small-scale and low-profit entities | |
| (92 | ) | |
| 18 | | |
| (19 | ) |
| Tax effect of tax relief | |
| (2 | ) | |
| - | | |
| - | |
| Tax effect of non-deductible items | |
| 77 | | |
| 76 | | |
| 141 | |
| Tax effect of expired tax attribute carryforwards | |
| 165 | | |
| 523 | | |
| 1,093 | |
| Tax effect of deferred tax effect of tax rate change | |
| (40 | ) | |
| - | | |
| - | |
| Changes in valuation allowance | |
| 4,498 | | |
| 2,379 | | |
| (595 | ) |
| Income tax expense | |
$ | 2,572 | | |
$ | 2,853 | | |
$ | 346 | |
|
| Schedule of Deferred Tax Assets |
As of December 31, 2024 and 2025, the significant components of the
deferred tax assets are summarized below:
| | |
As of December 31, | |
| | |
2024 | | |
2025 | |
| Deferred tax assets: | |
| | |
| |
| Temporary difference in accounts receivable recognition | |
$ | 5,570 | | |
$ | 5,815 | |
| Temporary difference in research and development costs | |
| 3,033 | | |
| 2,995 | |
| Accrued expense | |
| 391 | | |
| 408 | |
| Net operating loss carried forward | |
| 11,325 | | |
| 11,961 | |
| Share-based compensation | |
| 295 | | |
| 538 | |
| Allowance for credit losses | |
| 3,679 | | |
| 4,033 | |
| Total deferred tax assets | |
| 24,293 | | |
| 25,750 | |
| Valuation allowance | |
| (13,840 | ) | |
| (13,803 | ) |
| Deferred tax assets, net of valuation allowance | |
$ | 10,453 | | |
$ | 11,947 | |
|
| Schedule of Changes in Valuation Allowance |
Changes in valuation allowance are as follows:
| | |
As of December 31, | |
| | |
2024 | | |
2025 | |
| Balance at the beginning of the year | |
$ | 11,820 | | |
$ | 13,840 | |
| Additions/(Reversals) | |
| 2,344 | | |
| (642 | ) |
| Foreign currency translation adjustments | |
| (324 | ) | |
| 605 | |
| Balance at the end of the year | |
$ | 13,840 | | |
$ | 13,803 | |
|
| Schedule of Net Operating Loss Carryforwards |
As of December 31, 2025, net operating loss carryforwards will expire,
if unused, in the following amounts:
| 2026 | |
$ | 4,643 | |
| 2027 | |
| 16,976 | |
| 2028 | |
| 14,288 | |
| 2029 | |
| 6,664 | |
| 2030 | |
| 6,805 | |
| Indefinite | |
| 87,396 | |
| Total | |
$ | 136,772 | |
|